Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;13(6):551-573.
doi: 10.4155/fmc-2020-0308. Epub 2021 Feb 16.

Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators

Affiliations

Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators

Huiqun Wang et al. Future Med Chem. 2021 Mar.

Abstract

The modulation and selectivity mechanisms of seven mixed-action kappa opioid receptor (KOR)/mu opioid receptor (MOR) bitopic modulators were explored. Molecular modeling results indicated that the 'message' moiety of seven bitopic modulators shared the same binding mode with the orthosteric site of the KOR and MOR, whereas the 'address' moiety bound with different subdomains of the allosteric site of the KOR and MOR. The 'address' moiety of seven bitopic modulators bound to different subdomains of the allosteric site of the KOR and MOR may exhibit distinguishable allosteric modulations to the binding affinity and/or efficacy of the 'message' moiety. Moreover, the 3-hydroxy group on the phenolic moiety of the seven bitopic modulators induced selectivity to the KOR over the MOR.

Keywords: allosteric modulation mechanism; kappa opioid receptor (KOR)/mu opioid receptor (MOR); mixed-action KOR/MOR ligand; molecular dynamics simulations; psychostimulant abuse and addiction; selectivity.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

This work was partially supported by the Virginia Commonwealth University Center for High-Performance Computing and NIH/National Institute on Drug Abuse grants R01DA024022, R01DA044855 and UG3DA050311 (Y Zhang) and R01 DA041359, R21 DA045274 and P30 DA013429 (L-Y Liu-Chen). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Chemical structures of β-FNA, NFF, 42B, NBP, 3-dHNBP, NCP and 3-dHNCP with atom notations.
The ‘message’ moiety, linker and ‘address’ moiety in the structures are colored red, blue and magenta, respectively. β-FNA: β-funaltrexamine; NFF: Nalfurafine.
Figure 2.
Figure 2.. The RMSD and RMSF of the 14 complexes relative to their respective starting structures.
The RMSD of the backbone atoms of the proteins (A) and ligands (B), together with the RMSF of the backbone atoms of the β-FNA_MORinactive, β-FNA_KORactive, NFF_MORactive, NFF_KORactive, 42B_MORactive, 42B_KORactive, NBP_MORactive, NBP_KORactive, 3-dHNBP_MORinactive, 3-dHNBP_KORactive, NCP_MORactive, NCP_KORactive, 3-dHNCP_MORinactive and 3-dHNCP_KORactive complexes (C). β-FNA: β-funaltrexamine; KOR: Kappa opioid receptor; MOR: Mu opioid receptor; NFF: Nalfurafine; RMSD: Root-mean-square deviation; RMSF: Root-mean-square fluctuation.
Figure 3.
Figure 3.. The binding modes of the seven ligands in the KOR after MD simulations.
(A) β-FNA_KORactive, (B) NFF_KORactive, (C) 42B_KORactive, (D) NBP_KORactive, (E) 3-dHNBP_KORactive, (F) NCP_KORactive and (G) 3-dHNCP_KORactive. Active KOR shown as a cartoon model in light pink. β-FNA, NFF, 42B, NBP, 3-dHNBP, NCP and 3-dHNCP shown as stick-and-ball models. Key amino acid residues shown as stick models. Carbon atoms: β-FNA in white, NFF in magenta, 42B in cyan, NBP in orange, 3-dHNBP in green, NCP in pink, 3-dHNCP in dark cyan, key amino acid residues of the KOR in light cyan. Subdomain ABD2 of the allosteric site shown as a surface model in light orange. The red arrow in (A) represents the movement orientation of the ‘address’ moiety of β-FNA in the β-FNA_KORactive complex. β-FNA: β-funaltrexamine; KOR: Kappa opioid receptor; NFF: Nalfurafine.
Figure 4.
Figure 4.. Energy decomposition analyses of the seven ligands in the KOR.
(A) binding free energy, (B) van der Waals interaction and (C) net electrostatic interaction decomposition analyses of β-FNA_KORactive, NFF_KORactive, 42B_KORactive, NBP_KORactive, 3-dHNBP_KORactive, NCP_KORactive and 3-dHNCP_KORactive complexes. β-FNA: β-funaltrexamine; KOR: Kappa opioid receptor; NFF: Nalfurafine.
Figure 5.
Figure 5.. The binding modes of the seven ligands in the MOR after MD simulations.
(A) β-FNA_MORinactive, (B) 3dHNBP_MORinactive, (C) 3dHNCP_MORinactive, (D) NFF_MORactive, (E) 42B_MORactive, (F) NBP_MORactive and (G) NCP_MORactive complexes after MD simulations. Inactive and active MORs shown as cartoon models in light yellow and light blue, respectively. β-FNA, NFF, 42B, NBP, 3-dHNBP, NCP and 3-dHNCP shown as stick-and-ball models. Key amino acid residues shown as stick models. Carbon atoms: β-FNA in white, NFF in magenta, 42B in cyan, NBP in orange, 3-dHNBP in green, NCP in pink, 3-dHNCP in dark cyan, key amino acid residues of the MOR in dark violet. Subdomains ABD1 and ABD2 of the allosteric site shown as surface models in lemon and light orange, respectively. β-FNA: β-funaltrexamine; MOR: Mu opioid receptor; NFF: Nalfurafine.
Figure 6.
Figure 6.. Energy decomposition analyses of the seven ligands in the MOR.
(A & B) binding free energy, (C & D) van der Waals interaction and (E & F) net electrostatic interaction decomposition analyses of β-FNA_MORinactive, 3dHNBP_MORinactive, 3dHNCP_MORinactive, NFF_MORactive, 42B_MORactive, NBP_MORactive and NCP_MORactive complexes. β-FNA: β-funaltrexamine; MOR: Mu opioid receptor; NFF: Nalfurafine.

Similar articles

Cited by

References

    1. Substance Abuse and Mental Health Services Administration. www.samhsa.gov/data/
    1. White FJ, Kalivas PW. Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend. 51(1–2), 141–153 (1998). - PubMed
    1. Lott DC, Lott DC, Kim S-J et al. Serotonin transporter genotype and acute subjective response to amphetamine. Am. J. Addict. 15(5), 327–335 (2006). - PubMed
    1. Broadbear JH, Sumpter TL, Burke TF et al. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, β-funaltrexamine, and β-chlornaltrexamine. J. Pharmacol. Exp. Ther. 294(3), 933–940 (2000). - PubMed
    1. American Addiction Centers. https://americanaddictioncenters.org/stimulant-drugs

Publication types

LinkOut - more resources